Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artificial Tears to Prevent Nasolacrimal Duct Obstruction After Radioiodine Therapy
NCT05999630Phase 3Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Aug 2023
- Primary completion
- Dec 2027
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of methylcellulose in nasolacrimal duct obstruction (NLDO), sponsored by Vanderbilt University Medical Center. Started Aug 2023; status: recruiting.
02
Drugs
methylcellulose
03
Conditions
nasolacrimal duct obstruction (NLDO)
Beyond the preview
Go deeper on NCT05999630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05999630.